Phase 1b, multicenter, single blinded, placebo‐controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|119|24|4268-4276

ISSN： 0008-543x

Source： CANCER, Vol.119, Iss.24, 2013-12, pp. : 4268-4276

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase 1, placebo-controlled, randomised, double-blind (within dose panels) study evaluating the safety, tolerability and pharmacokinetics of intravenous NXY-059 in Japanese subjects

By Watabe Mitsuo   Cheng Yi-Fang   Nilsson Dag   Itoh Yohji   Kumagai Yuji  

Current Medical Research and Opinion, Vol. 23, Iss. 8, 2007-08 ,pp. : 1849-1857

Informa Healthcare

Access to resources Recommend Favorite

A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors

By Kellum A.   Jagiello-Gruszfeld A.   Bondarenko I.N.   Patwardhan R.   Messam C.   Mostafa Kamel Y.  

Current Medical Research and Opinion, Vol. 26, Iss. 10, 2010-10 ,pp. : 2339-2346

Informa Healthcare

Access to resources Recommend Favorite

A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3481-3490

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 32, Iss. 1, 2018-01 ,pp. : 145-151

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 2a randomized, double‐blind, placebo‐controlled, sequential dose‐escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate‐to‐severe psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 3, 2015-09 ,pp. : 767-776

John Wiley & Sons Inc

Access to resources Recommend Favorite